VIDEO: CAR T-cell therapy ‘holding up as a possible breakthrough’ in autoimmune disease
Click Here to Manage Email Alerts
In this video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, calls out top stories in the July issue, including a cover story on chimeric antigen receptor T-cell therapy.
“I just got back from EULAR Vienna 2024, and really the focus of that meeting, the buzz of that meeting, was on CAR T-cells,” Calabrese said. “It is still holding up as a possible breakthrough in the treatment of autoimmune disease.”
The story offers insights from several experts — including a pioneer of the field, Georg Schett, MD — on what CAR T-cell therapy may portend for the future of autoimmune disease. It also tackles the question of whether rheumatologists can begin talking about a cure for some of the intractable conditions they treat.
Calabrese also highlighted a feature story on Mark Cuban’s Cost Plus Drug Company, which may still be “flying under the radar” 2 years after its launch.
“I’m a big fan,” he said. “This guy is putting it to the PBMs, and I’m all supportive of it.”
Finally, Calabrese discussed recent coverage of declining Medicare reimbursements, which he said is “on an untenable track.”
Check out the July issue of Healio Rheumatology by clicking here.
Collapse
Healio Interviews
Click Here to Manage Email Alerts